Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW Trial - PubMed
3 days ago
- #Type 2 Diabetes
- #Semaglutide
- #Chronic Kidney Disease
- Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD) in the FLOW trial.
- The trial was a double-blind, randomized, placebo-controlled study with a median follow-up of 3.4 years.
- Participants had T2D and varying levels of eGFR and UACR, and were randomized to receive either semaglutide or placebo.
- The primary outcome showed a significant reduction in kidney disease events and all-cause death with semaglutide compared to placebo (HR 0.76; 95% CI, 0.66-0.88).
- All-cause death was also lower in the semaglutide group (HR 0.80; 95% CI, 0.67-0.95).
- The benefits of semaglutide were consistent across different baseline eGFR and UACR subgroups.
- The study supports the use of semaglutide in T2D patients across a wide spectrum of CKD severity, including advanced CKD.